EntryPoint Capital’s Twist Bioscience TWST Stock Holding History

EntryPoint Capital’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,040	Closed	-$420K	–	955
2024 Q4	$420K	Buy	+9,040	New	+$409K	0.18%	185

Other funds holding TWST

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

EntryPoint Capital's TWST Position: Q1 2025 in Review

EntryPoint Capital sold out of Twist Bioscience (TWST) in Q1 2025, closing a stake of 9,040 shares — an estimated $420K sold.

EntryPoint Capital first reported a position in TWST in Q4 2024 and held it in 1 quarter. The position peaked at $420K in Q4 2024. 262 funds tracked by Wall St. Rank hold TWST as of Q1 2025.

EntryPoint Capital reported no remaining Twist Bioscience position as of Q1 2025 after selling out during the quarter.
EntryPoint Capital sold 9,040 Twist Bioscience shares in Q1 2025, an estimated $420K.
EntryPoint Capital first reported a position in Twist Bioscience in Q4 2024 and held it in 1 quarter.
EntryPoint Capital's Twist Bioscience position peaked at $420K in Q4 2024.
262 funds tracked by Wall St. Rank held Twist Bioscience as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.